Results 171 to 180 of about 80,369 (215)

Spatial distribution and clustering of multidrug-resistant tuberculosis in Uganda: a nationwide ecological study (2014-2023)

Akello SR, Alunyo JP, Matovu JK, Emetu J, Oposhia J, Ssanyu GN, Bogere MN, Birungi P, Madenje M, Okalebo BC, Okiror W, Paasi G, Nsubuga S, Aujo D, Okibure A, Mukunya D, Olupot-Olupot P.   +16 more
europepmc   +1 more source

Drug-Resistant Tuberculous Meningitis (DR-TBM) in a Low-Incidence Setting: Two Cases and an Evidence Review Highlighting Key Advances and Knowledge Gaps in Clinical Management. [PDF]

Open Forum Infect Dis
Boschung KF, Wong PHP, Werry D, Sekirov I, Turvey SL, Cook VJ, Johnston J, Connors WJA.   +7 more
europepmc   +1 more source

Home-Based Monitoring of Treatment-Related Adverse Events during Drug-Resistant Tuberculosis Treatment, India, 2020-2024. [PDF]

Emerg Infect Dis
Ahson M, Shah D, Bhide S, Deshmukh R, Smith JP, Waghmare S, Kaipilyawar S, Puri V, Khetade DK, Yeldandi V, Date A, Moonan PK, Ho CS.   +12 more
europepmc   +1 more source

Targeted next-generation sequencing for comprehensive diagnosis and drug resistance detection in pulmonary and extrapulmonary tuberculosis: a single-center retrospective study. [PDF]

Microbiol Spectr
Dai J, Li Q, Wan J, Sun F, Zhou G, Yang M, Dong C, Fang Y, Li L, Wang L, Liu G.   +10 more
europepmc   +1 more source

High efficacy of BPaL among patients infected with <i>Mycobacterium tuberculosis</i> lineage 1 in the Philippines. [PDF]

IJTLD Open
Flores I, Tujan MAA, Basilio R, Dizon TJR, Lim DR, Reyes LT, Reyes RVAG, Rojas S, Valencia AK, Capin JB, Mirtskhulava V, Palparan AG, Cabalitan C, Carpin PJ, Malbacias C, Lee JS, Gebhard A, Quelapio M, Timm J.   +18 more
europepmc   +1 more source

Spatial autocorrelation and hotspot dynamics of multidrug-resistant tuberculosis in Uganda: a district-level LISA analysis

Akello SR, Alunyo JP, Matovu JK, Emetu J, Mugasha E, Paasi G, Okibure A, Mukunya D, Olupot-Olupot P.   +8 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Multidrug-resistant tuberculosis

Nature Reviews Disease Primers
Tuberculosis (TB) remains the foremost cause of death by an infectious disease globally. Multidrug-resistant or rifampicin-resistant TB (MDR/RR-TB; resistance to rifampicin and isoniazid, or rifampicin alone) is a burgeoning public health challenge in several parts of the world, and especially Eastern Europe, Russia, Asia and sub-Saharan Africa.
Keertan Dheda, Fuad Mirzayev, Daniela Maria Cirillo, Zarir Udwadia, Kelly E. Dooley, Kwok-Chiu Chang, Shaheed Vally Omar, Anja Reuter, Tahlia Perumal, C. Robert Horsburgh, Megan Murray, Christoph Lange   +11 more
openaire   +4 more sources

Multidrug resistant cervical tuberculosis

American Journal of Otolaryngology, 1999
Tuberculosis (TB) remains a global health problem, with an annual incidence of 8 to 10 million cases and the death of 3 million people year1y.l Despite the continuous decline of TB in the United States since the 185Os, an increase in new TB cases was observed in 1985.
A J, Vartanian, A, Alvi
openaire   +2 more sources